Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564042 · ClinicalTrials.gov registry record · Phase 2
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
NCT02564042 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 227 participants.
The verdict
NCT02564042, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of two concentrations (0.5 percent \[%\] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque psoriasis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and dosing frequency in future clinical safety and efficacy studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all psoriasis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adult males and females subjects with plaque psoriasis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.
Interventions
- DRUG Vehicle cream
- DRUG GSK2894512 1% Cream
- DRUG GSK2894512 0.5% Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2015-11-23 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564042
The ClinicalTrials.gov registry entry for NCT02564042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle cream is the first listed.
NCT02564042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564042 about?
NCT02564042 is a clinical study titled "A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis". This study will evaluate the efficacy and safety of two concentrations (0.5 percent \[%\] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque psoriasis. Results from this study will be considered when selecting th...
What is the current status of trial NCT02564042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2015-11-23. Estimated completion is 2016-10-05.
What interventions are being tested in trial NCT02564042?
The interventions under investigation include: Vehicle cream (DRUG), GSK2894512 1% Cream (DRUG), GSK2894512 0.5% Cream (DRUG).
Who is sponsoring clinical trial NCT02564042?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.